Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.
Advanced glycation end-products (AGEs) are molecules formed during a non-enzymatic reaction between proteins and sugar residues, called the Maillard reaction. AGEs accumulate in the human body with age, and accumulation is accelerated in the presence of diabetes mellitus. In patients with diabetes, AGE accumulation is associated with the development of cardiac dysfunction. Enhanced AGE accumulation is not restricted to patients with diabetes, but can also occur in renal failure, enhanced states of oxidative stress, and by an increased intake of AGEs. Several lines of evidence suggest that AGEs are related to the development and progression of heart failure in non-diabetic patients as well. Preliminary small intervention studies with AGE cross-link breakers in heart failure patients have shown promising results. In this review, the role of AGEs in the development of heart failure and the role of AGE intervention as a possible treatment for heart failure are discussed.
Hartog
Jasper W L
JW
Department of Cardiology, Thoraxcenter, University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. j.w.l.hartog@thorax.umcg.nl
Voors
Adriaan A
AA
Bakker
Stephan J L
SJ
Smit
Andries J
AJ
van Veldhuisen
Dirk J
DJ
D000818:Animals; D018450:Disease Progression; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006333:Heart Failure / Q000378:metabolism* / Q000503:physiopathology*; D006801:Humans; D009200:Myocardial Contraction / Q000502:physiology*; D018384:Oxidative Stress; D013599:Systole
D017127:Glycation End Products, Advanced